Manuel
Barreiro de Acosta
Hospital Universitario Virgen Macarena
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (20)
2024
-
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis
Gastroenterologia y Hepatologia, Vol. 47, Núm. 5, pp. 522-552
2022
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953
-
Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study
Digestive and Liver Disease, Vol. 54, Núm. 1, pp. 76-83
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382
2020
-
Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 12, pp. 1514-1522
-
Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: The VERNE study
BMJ Open Gastroenterology, Vol. 7, Núm. 1
2019
-
Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicentre Study
Journal of Crohn's and Colitis, Vol. 13, Núm. 8, pp. 996-1002
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
-
Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study
Inflammatory Bowel Diseases, Vol. 23, Núm. 10, pp. 1840-1846
-
Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 12, pp. 1430-1439
2016
-
Urine metabolome profiling of immune-mediated inflammatory diseases
BMC Medicine, Vol. 14, Núm. 1
2013
-
Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease
Digestive Diseases and Sciences, Vol. 58, Núm. 10, pp. 2949-2954
2012
-
Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: A multicentre study
Alimentary Pharmacology and Therapeutics, Vol. 35, Núm. 2, pp. 275-283